VEA
QNCX icon

Virtus ETF Advisers’s Quince Therapeutics QNCX Stock Holding History

Virtus ETF Advisers’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-68
Closed -$85K – 467
2022
Q1 		$85K Sell
68
-4
-6% -$5.44K 0.04% 329
2021
Q4 		$183K Buy
72
+50
+227% +$305K 0.07% 241
2021
Q3 		$410K Sell
22
-2
-8% -$31.8K 0.18% 168
2021
Q2 		$249K Sell
24
-26
-52% -$218K 0.1% 213
2021
Q1 		$359K Buy
50
+1
+2% +$7.2K 0.15% 205
2020
Q4 		$272K Buy
49
+15
+44% +$133K 0.11% 269
2020
Q3 		$342K Sell
34
-5
-13% -$45.5K 0.18% 192
2020
Q2 		$360K Sell
39
-7
-15% -$64.1K 0.17% 252
2020
Q1 		$420K Sell
46
-7
-13% -$69.1K 0.17% 192
2019
Q4 		$592K Buy
+53
New +$320K 0.1% 191

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Virtus ETF Advisers's QNCX Position: Q2 2022 in Review

Virtus ETF Advisers sold out of Quince Therapeutics (QNCX) in Q2 2022, closing a stake of 68 shares — an estimated $85K sold.

Virtus ETF Advisers first reported a position in QNCX in Q4 2019 and held it in 10 quarters. The position peaked at $592K in Q4 2019. 66 funds tracked by Wall St. Rank hold QNCX as of Q2 2022.

  • Virtus ETF Advisers reported no remaining Quince Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Virtus ETF Advisers sold 68 Quince Therapeutics shares in Q2 2022, an estimated $85K.
  • Virtus ETF Advisers first reported a position in Quince Therapeutics in Q4 2019 and held it in 10 quarters.
  • Virtus ETF Advisers's Quince Therapeutics position peaked at $592K in Q4 2019.
  • 66 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2022.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.